Logo
x

Search category

Subscribe Now

Incyte

Incyte Reports P-III Study (TRuE-AD3) Results of Opzelura (ruxolitinib) for Children with Atopic Dermatitis

Incyte Reports P-III Study (TRuE-AD3) Results of Opzelura (ruxolitinib) for Children with Atopic Dermatitis

  • July 12, 2023
Incyte Presents P-II Trial (SCRATCH-AD) Results of Opzelura (ruxolitinib) for the Treatment of Atopic Dermatitis at RAD 2023

Incyte Presents P-II Trial (SCRATCH-AD) Results of Opzelura (ruxolitinib) for the Treatment of Atopic Dermatitis at RAD 2023

  • May 2, 2023
Incyte’s Opzelura (ruxolitinib) Receives EC’s Approval for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

Incyte’s Opzelura (ruxolitinib) Receives EC’s Approval for Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescent...

  • April 21, 2023
Insights+: The US FDA New Drug Approvals in March 2023

Insights+: The US FDA New Drug Approvals in March 2023

  • April 19, 2023
Incyte’s Pemazyre (pemigatinib) Receives MHLW Approval for Myeloid/Lymphoid Neoplasms

Incyte’s Pemazyre (pemigatinib) Receives MHLW Approval for Myeloid/Lymphoid Neoplasms

  • March 27, 2023
Incyte’s Zynyz (retifanlimab-Dlwr) Receives the US FDA’s Approval for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma

Incyte’s Zynyz (retifanlimab-Dlwr) Receives the US FDA’s Approval for Metastatic or Recurrent Locally Advanced Merkel Cell Carcino...

  • March 23, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.